Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kilitch Drugs (India)NSE:KILITCH +2.81%84 EV-to-EBITDA is 12.61 as of Aug. 25, 2026, which is 35% below its 10-year median of 19.28. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹226.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 735 Drug Manufacturers companies, Kilitch Drugs (India) ranks better than 51.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kilitch Drugs (India)'s enterprise value is ₹6,035 Mil.
Kilitch Drugs (India)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹478 Mil. Therefore, Kilitch Drugs (India)'s EV-to-EBITDA for today is 12.61.
The historical rank and industry rank for Kilitch Drugs (India)'s EV-to-EBITDA or its related term are showing as below:
NSE:KILITCH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.78 Med: 19.28 Max: 90.49
Current: 12.61
During the past 13 years, the highest EV-to-EBITDA of Kilitch Drugs (India) was 90.49. The lowest was 8.78. And the median was 19.28.
NSE:KILITCH's EV-to-EBITDA is ranked better than 51.97% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.46
vs NSE:KILITCH: 12.61
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kilitch Drugs (India)'s PE Ratio (TTM) for today is calculated as:
Kilitch Drugs (India)'s share price for today is ₹166.89.
Kilitch Drugs (India)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8.805.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Kilitch Drugs (India) EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Kilitch Drugs (India)'s EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kilitch Drugs (India) EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kilitch Drugs (India)'s EV-to-EBITDA falls into.
Kilitch Drugs (India)'s current Enterprise Value is ₹6,035 Mil.
Kilitch Drugs (India)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹478 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kilitch Drugs (India) (NSE:KILITCH) has a EV-to-EBITDA of 12.61 as of Aug. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kilitch Drugs (India). This is 35% below median its historical median of 19.28. Over the past decade, Kilitch Drugs (India)'s EV-to-EBITDA has ranged from 8.78 to 90.49. According to the industry distribution chart, Kilitch Drugs (India) ranks #353 out of 735 companies in the Drug Manufacturers industry, placing it in the top 48%.
Is Kilitch Drugs (India)'s EV-to-EBITDA too high?
Kilitch Drugs (India)'s current EV-to-EBITDA of 12.61 is 35% below median its 10-year median of 19.28. Over the past 10 years, this metric has ranged from a low of 8.78 to a high of 90.49. The Drug Manufacturers industry median EV-to-EBITDA is 13.46. Kilitch Drugs (India)'s value of 12.61 is 6.3% below this industry median. Based on the distribution chart, Kilitch Drugs (India) ranks #353 out of 735 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kilitch Drugs (India) ranks #353 out of 735 companies for EV-to-EBITDA. This puts Kilitch Drugs (India) in the upper half of its industry. The industry median EV-to-EBITDA is 13.46. Kilitch Drugs (India)'s value of 12.61 is 6.3% below this benchmark. Historically, Kilitch Drugs (India)'s own EV-to-EBITDA has ranged from 8.78 to 90.49 over the past decade. While the company's 10-year median is 19.28 vs. the industry median of 13.46, Kilitch Drugs (India) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.46, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kilitch Drugs (India)'s current EV-to-EBITDA of 12.61 is 6.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kilitch Drugs (India). For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kilitch Drugs (India)'s current EV-to-EBITDA is 12.61, which is 35% below median its own 10-year median of 19.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹226.28, compared to a current price of ₹166.89 — trading 26.2% below its estimated fair value. The current EV-to-EBITDA is 12.61, which is 35% below median its 10-year median of 19.28 and 6.3% below the Drug Manufacturers industry median of 13.46. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current EV-to-EBITDA is 12.61 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?
Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued.
The current stock price of ₹166.89 is trading 26.2% below its estimated GF Value™ of ₹226.28.
GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.
Key valuation signals for NSE:KILITCH:
EV-to-EBITDA: 12.61 (35% below median its 10-year median of 19.28)
GF Value™: ₹226.28 vs. price of ₹166.89 (26.2% below fair value)
Industry Position: 6.3% below the Drug Manufacturers median (#353 of 735)
No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score
Get the complete analysis for NSE:KILITCH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KILITCH has been successfully added to your 
